Critical Care Antiarrhythmic Drugs Market to Rise at 5.6% CAGR till 2027; Increasing Incidence of Supraventricular Arrhythmia Worldwide to Aid Market Expansion

The global critical care antiarrhythmic drugs market size is projected to reach USD 1,319.7 million by 2027 on account of the rising demand for biologics for the treatment of ventricular arrhythmias, states Fortune Business Insights™ in its report, titled “Critical Care Antiarrhythmic Drugs Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Beta Blockers, Calcium Channel Blockers, Sodium Channel Blockers, Potassium Channel Blockers, and Others),  By Disease Type (Supraventricular Arrhythmias, Ventricular Arrhythmias, and Others), and Regional Forecast, 2020-2027”. The report further states that the value of the market in 2019 stood at USD 796.8 million and that the market is expected to register a CAGR of 5.6% from 2020 to 2027.

The COVID-19 pandemic has had a positive impact on the critical care antiarrhythmic drugs market growth as the coronavirus has been proven to worsen pre-existing cardiac abnormalities in COVID patients. Medications for managing cardiovascular diseases, which already have a high incidence rate globally, have become critical amid the current pandemic. The soaring demand for such treatments has enabled the market to showcase a CAGR of 12.9% in 2020.

AltaThera Pharmaceuticals Attains FDA Nod for New Indications of Sotalol IV

In March 2020, AltaThera Pharmaceuticals announced that it has secured clearance from the US Food and Drug Administration (FDA) for Sotalol IV in patients with atrial fibrillation (AFib). The new approval allows Sotalol to be used for 1-day hospital outpatient AFib treatment and escalated doses for existing patients. Approved on the lines of the FDA’s inventive Model-Informed Drug Development regulatory path, the new indication will allow physicians and health professionals to start Sotalol therapy for arrhythmia patients, with the potential of reducing hospital costs and substantially improving patient outcomes.

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/critical-care-antiarrhythmic-drugs-market-104703

Exciting Research on Advanced Arrhythmia Therapies to Fuel Demand for Critical Care Antiarrhythmic Drugs

The numerous complications associated with arrhythmias have driven up the demand for research in this domain. Several academics, government organizations, and private institutes are actively participating in research studies to investigate the efficacy of innovative therapies for cardiac abnormalities. For example, a study published in the New England Journal of Medicine in December 2020 found that Edobaxan is a highly effective placebo in preventing systemic embolism and stroke in elderly Japanese patients with non-valvular atrial fibrillation. In November 2020, medical professionals from the Cleveland Clinic revealed that cryoballoon ablation is a superior therapy to inhibit the recurrence of atrial arrhythmia in patients suffering from paroxysmal atrial fibrillation. Further, in October 2020, the Skolkovo Institute of Science and Technology in Russia developed a new approach based on machine learning technology to identify atrial fibrillation drivers to enable targeted medical interventions for patients with cardiac issues. Growing body of research of this kind is, thus, significantly raising the potential of this market for critical care antiarrhythmic drugs.

Key Players to Deepen Market Footprint through Innovations

Leading competitors in the critical care antiarrhythmogenic drugs market are cementing their position by developing and launching innovative drugs and therapies to treat life-threatening cardiac conditions. With heavy investments in research and development activities, these companies are making notable strides in the heart health domain, serving the growing needs of patients with complicated heart conditions. Moreover, the COVID-19 pandemic has suffused companies with a new energy to create novel, effective formulations to aid the fight not just against the coronavirus, but also against increasing prevalence of cardiovascular conditions worldwide.

Industry Development:

• June 2020: Upsher-Smith Laboratories released the Propafenone Hydrochloride Extended-Release Capsules in 225 mg, 325 mg and 425 mg strengths. The drugs are indicated for suppressing ventricular arrhythmias in patients with cardiac disorders.

List of Key Players Profiled in the Critical Care Antiarrhythmic Drugs Market Report:

• Upsher-Smith Laboratories, LLC. (Minnesota, U.S.)
• GlaxoSmithKline plc (London, U.K.)
• Baxter International Inc. (Deerfield, U.S.)
• Novartis AG (Basel, Switzerland)
• Amomed Pharma GmbH (Vienna, Austria)
• Mayne Pharma (Salisbury South, Australia)
• Sanofi (Paris, France)
• Mylan N.V. (Pennsylvania, U.S.)
• Pfizer Inc. (New York, U.S.)

Further Report Findings:

• The beta blockers segment led the market with a share of 34.6% in 2019 owing to the proven efficacy of these therapies in managing and treating arrhythmias.
• North America is expected to command the critical care antiarrhythmic drugs market share during the forecast period, primarily due to the increasing number of drug launches by large pharmaceutical companies in the region. The North America market size stood at USD 359.2 million in 2019.  

Table of Segmentation